Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Oklahoma for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Oklahoma only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Oklahoma (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Kevin Weibel (NPI 1104864016)

Field	Value
Entity Type	Individual
Organization	Kevin Weibel
Address	12697 E 51st St
City	Tulsa
State	OK
ZIP	74146
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 3, 2006

Payer Source	Total Paid
Medicare	$1.7M
Medicaid	$0

Key Findings

KEVIN WEIBEL is a Hematology & Oncology Physician in TULSA, OK with total Medicare revenue of $1.7M and no Medicaid billing on file (none below). The absence of Medicaid claims makes this effectively a Medicare-centric practice and concentrates payer exposure on a single federal program rather than a mixed commercial/Medicaid portfolio.

Revenue is highly concentrated in a small set of high-cost oncology drugs: the precomputed top three Medicare codes account for 61.6% of this provider's Medicare revenue, driven by J9299 ($353.3K revenue, 22.6% of Medicare revenue), J9271 ($344K revenue, 22.0% of Medicare revenue), and J9144 ($266.8K revenue, 17.1% of Medicare revenue). This concentration indicates that a majority of billings are coming from administration of a few biologic/immunotherapy agents.

The code mix and descriptions point to a predominantly infusion-based oncology operation: high-revenue biologic and checkpoint inhibitor injections (J9299, J9271, J9144) alongside chemotherapy administration codes (96413) and infusion add-ons (96367). Support services are present in-house, with PET/CT imaging (78815) and lab panels (80053, 85025) appearing in the top codes, suggesting an outpatient clinic that coordinates diagnostics, infusion, and routine oncology follow-up.

Competitive standing on the highest-revenue drugs is modest rather than dominant at the national level: J9299 ranks #255 of 505 providers nationally (49th percentile; typical, unremarkable volume for this code), J9271 ranks #1402 of 1841 providers nationally (23th percentile; typical, unremarkable volume for this code), and J9144 ranks #362 of 615 providers nationally (39th percentile; typical, unremarkable volume for this code). These ranks imply the provider is an active user of these agents but not a major national outlier or market leader for any single high-cost drug.

Operational throughput appears comparatively stronger for routine visits, infusion administration, and lab work: 99214 (622 claims, $82 avg paid/claim, $51K revenue; ranks #33202 of 479517 providers nationally, 93th percentile; typical, unremarkable volume for this code), 96413 (428 claims, $91 avg paid/claim, $38.9K revenue; 87th percentile), 96367 (564 claims, $20 avg paid/claim, $11.3K revenue; 92th percentile), and lab CPTs 80053 and 85025 (94th and 92th percentiles respectively). This combination—high percentiles on E/M, infusion, and labs—suggests steady patient volumes and a clinic workflow that handles frequent visits and routine supportive-care services.

There are some specialized and low-standing items in the national ranking that may reflect niche or limited use locally: J1930 (lanreotide) is relatively rare in national comparison (2.2K claims, $43 avg paid/claim, $92.9K revenue; ranks #54 of 56 providers nationally, 4th percentile), and some biosimilars show very low national placement (e.g., Q5122 ranks #236 of 239 providers nationally, 0th percentile). At the same time, several supportive-care injections show very high claim counts but low per-claim payment (e.g., J1439: 15.8K claims, $1 avg paid/claim, $15.8K revenue), indicating operational emphasis on high-frequency, low-dollar supportive medications.

From a business-risk and contracting perspective, the combination of long tenure and payer concentration is material: the NPI was enumerated 2006-06-03 (~20 years ago), indicating an established practitioner, but reliance on Medicare ($1.7M) with no Medicaid billed introduces single-payer exposure and may limit leverage in state Medicaid networks. For payers and analysts, the profile signals a stable, clinic-centered oncology practice with concentrated drug spend that would be sensitive to changes in Medicare oncology reimbursement or shifts in drug utilization.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

83 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	14,720	$20	$353.3K
J9271	Injection, pembrolizumab, 1 mg	8,000	$40	$344K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,020	$40	$266.8K
J1930	Injection, lanreotide, 1 mg	2,160	$40	$92.9K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	2,640	$30	$66K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	1,490	$40	$53.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	620	$80	$51K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	40	$1,000	$43.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	430	$90	$38.9K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	1,480	$30	$37K

Showing 1–10 of 83

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 83 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Oklahoma Distribution

Kevin Weibel — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Oklahoma

Full comparison — all codes billed, vs. state median

83 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	8	10	10,600	$40	$466.9K
J9299	4	10	14,050	$20	$324.4K
J9144	2	10	6,480	$40	$248.5K
J1930	5	10	2,910	$40	$137.2K
J1569	13	20	3,670	$30	$125.8K
J0897	67	70	2,130	$20	$91.2K
J1449	7	10	3,040	$30	$78.5K
Q5118	3	10	1,480	$30	$37.8K
J1627	7	10	6,100	$1	$30.1K
78815	57	80	80	$230	$29.2K

Showing 1–10 of 83

Related Providers

Other providers that share a Tax Identification Number (TIN) with Kevin Weibel, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Stillwater Medical Center Authority	OK	General Acute Care Hospital	$0	$15.7M
Stillwater Medical Center Authority	OK	Family Medicine Physician	$0	$13.2M
Stillwater Medical Center Authority	OK	Rural Acute Care Hospital	$0	$3.3M
Scott Cole	OK	Hematology & Oncology Physician	$2.3M	$0
Mark Jennings	TX	Internal Medicine Physician	$2.1M	$0
Matthew Flood	OK	Ophthalmology Physician	$1.1M	$0
Eric Thomas	OK	Obstetrics & Gynecology Physician	$536.3K	$0
Steven Cummings	OK	Internal Medicine Physician	$359.5K	$0
Andrea Fraley	OK	Sports Medicine (Physical Medicine & Rehabilitation) Physician	$355.9K	$0
Jeffrey Miller	OK	Pain Medicine (Anesthesiology) Physician	$317.3K	$0

Nearby Providers

Other providers in the same ZIP code as Kevin Weibel, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Option 1 Nutrition Solutions LLC	OK	Durable Medical Equipment & Medical Supplies	$0	$18.8M
Regional Medical Laboratory, Inc	OK	Clinical Medical Laboratory	$0	$17.6M
Labcorp Oklahoma, Inc.	OK	Clinical Medical Laboratory	$6.8M	$7.8M
Access Pain Solutions	OK	Pain Medicine Physician	$0	$13.1M
Osu Center For Health Sciences	OK	Medical Specialty Clinic/Center	$0	$10.5M
Advanced Pediatric Care	OK	Durable Medical Equipment & Medical Supplies	$0	$4.9M
Asm LLC	OK	Customized Equipment (DME)	$0	$4.7M
Pathology Laboratory Associates, Inc.	OK	Anatomic Pathology & Clinical Pathology Physician	$22.2K	$3.9M
Sleep Management, L.L.C.	OK	Oxygen Equipment & Supplies (DME)	$0	$3.6M
Tulsa Bone & Joint Associates PC	OK	Orthopaedic Surgery Physician	$0	$3M

Kevin Weibel — Billing Profile & Reimbursement Data

Sign up for Kevin Weibel — Billing Profile & Reimbursement Data policy alerts

Kevin Weibel — Billing Profile & Reimbursement Data

Sign up for Kevin Weibel — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References